Core Points - Sable Offshore Corp. has issued a response to the California Office of the State Fire Marshal regarding regulatory matters [1] Group 1 - The company is addressing compliance and safety regulations as mandated by the California Office of the State Fire Marshal [1] - The response indicates the company's commitment to adhering to state regulations and ensuring operational safety [1]

Core Points - MercadoLibre, Inc. plans to release its financial results for the third fiscal quarter ending September 30, 2025, on October 29, 2025 [1] - The company will host a video conference for its earnings results, along with a conference call and audio webcast, on the same date at 5:00 p.m. Eastern Time [1] Financial Results Announcement - The financial results will cover the third fiscal quarter of 2025 [1] - The scheduled release date for the financial results is October 29, 2025 [1] - Investors, analysts, and the general market can access the video webcast and live audio [1]

Group 1 - POET Technologies is positioned in a significant tech boom, focusing on optical interposer technology that addresses a critical bottleneck in the industry [1] - The company is viewed favorably by GARP-themed investors, particularly those seeking aggressive growth prospects and profitability within 1-2 years [1] - The investment philosophy of the associated analyst emphasizes long-term discipline and consistent alpha generation, while also acknowledging the presence of risk [1]

Core Insights - Unilever reported a 4% underlying sales growth in the third quarter of 2025, with volume growth accelerating to 1.7% excluding Ice Cream, despite challenging market conditions [3] - The growth was broad-based across all business groups, each achieving underlying sales growth above 3% [3] - The performance aligns with Unilever's full-year outlook, showcasing strong innovation, improved execution, and a strategic shift towards premium segments and fast-growing channels [4] Business Performance - Major growth engines, specifically Beauty & Wellbeing and Personal Care, delivered particularly strong performances [4] - The company continues to focus on its power brands, which are integral to its growth strategy [4] Leadership Update - Srini Phatak has been confirmed as the Chief Financial Officer, bringing extensive experience and expertise to the company [2]

Economic Overview - The U.S. economy is experiencing significant growth, with a reported 4% growth rate according to the Atlanta Fed, while global economic performance is lagging behind [2][4][10] - Commodity prices, including groceries, energy, and other essentials, are declining, indicating a potential deflationary trend despite expectations of tariff-induced inflation [1][2][4] Federal Reserve Policies - There is a call for a change in the Federal Reserve's management and operating framework to better align with the current economic conditions and support Main Street rather than just Wall Street [3][5][6] - The Fed's current policies are seen as counterproductive, contributing to stagflation, and there is a suggestion to lower the target interest rate from 4% to 2% to stimulate the housing market and overall economic activity [8][10] Government Policies Impact - The policies of the current administration are credited with driving economic growth and lowering prices, contrasting with the previous administration's approach [4][10][12] - A strong emphasis is placed on the need for coordination between government policies and the Federal Reserve to avoid conflicting objectives that could hinder economic progress [12]

Adventist Health System West sold out its entire position in the iShares MSCI Emerging Markets ex China ETF (EMXC), according to an SEC filing released on Tuesday.What HappenedAccording to a filing with the Securities and Exchange Commission on Tuesday, Adventist Health System West liquidated its entire holding in the iShares MSCI Emerging Markets ex China ETF (EMXC +0.48%) during the third quarter. The fund sold 837,660 shares, with an estimated $52.9 million.What Else to KnowTop holdings after the filing: ...

Core Insights - The US FDA has approved Blenrep (belantamab mafodotin-blmf) in combination with bortezomib and dexamethasone for treating adult patients with relapsed or refractory multiple myeloma who have undergone at least two prior lines of therapy [1][14][6] Group 1: Approval and Clinical Data - Blenrep's approval is based on the DREAMM-7 phase III trial, which showed a 51% reduction in the risk of death (HR 0.49) and a tripled median progression-free survival (PFS) of 31.3 months compared to 10.4 months for a daratumumab-based triplet [2][6][10] - The safety profile of the Blenrep combination aligns with the known profiles of the individual agents, indicating manageable side effects [2][6] Group 2: Market Need and Accessibility - There is a significant unmet need for new therapies in multiple myeloma, as nearly all patients experience relapse, and existing treatments often lead to suboptimal outcomes [3][6] - Blenrep is the only anti-BCMA agent accessible in community settings, where approximately 70% of patients receive care, fulfilling a major patient need [3][6] Group 3: Ongoing Development and Future Trials - GSK is advancing the DREAMM clinical program to explore Blenrep's efficacy in earlier lines of treatment, with follow-up data expected in early 2028 [7][6] - DREAMM-10, a phase III trial for newly diagnosed transplant-ineligible patients, was initiated in Q4-2024, with interim efficacy data anticipated in early 2028 [7][12] Group 4: Global Approvals and Future Applications - Blenrep has received approvals in multiple markets, including the European Union, UK, Japan, Canada, Switzerland, and Brazil, with applications under review in other regions, including China [8][6]

A HDR evening shot taken at sunset of the Tokyo skyline.Asia-Pacific markets rose Friday, after the White House said that U.S. President Donald Trump and China's President Xi Jinping were set to hold talks next week.U.S. Press Secretary Karoline Leavitt said Trump will leave for Malaysia late Friday and then travel to Japan and South Korea, meeting Xi next Thursday after speaking at the Asia-Pacific Economic Cooperation CEO Summit, Reuters reported.Japan's benchmark Nikkei 225 index climbed 0.78%, while the ...

Raymond James Financial, Inc. (NYSE:RJF) has a new price target of $194, suggesting a potential increase of 17.59%.The competitive credit market could impact Raymond James' loan quality and pricing strategies.RJF's stock experienced significant volatility over the past year, with a high of $177.66 and a low of $117.57.Raymond James Financial, Inc. (NYSE:RJF) is a diversified financial services company offering investment banking, asset management, and financial planning services. It competes with financial ...

: Americans struggling with high borrowing costs may finally be getting some relief as the average rate for a Freddie Mac: Mortgage rates fall nearly a full point lower than early 2025Sam Khater, Freddie Mac’s chief economist, said that, “At the start of 2025, the 30-year fixed-rate mortgage surpassed 7%, while today it hovers nearly a full percentage point lower,” as quoted by CNN.The decline comes as home prices soften in many major metro areas, prompting sidelined buyers to consider entering the market ...